- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
14 result(s) found for: Cephalosporin C.
Displaying page 1 of 1.
EudraCT Number: 2023-000052-38 | Sponsor Protocol Number: FOSFO3GCRE | Start Date*: 2023-06-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Enterobacterales. | |||||||||||||
Medical condition: urinary tract infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004615-45 | Sponsor Protocol Number: BPR-PIP-002 | Start Date*: 2016-12-02 | ||||||||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | ||||||||||||||||||
Full Title: A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephal... | ||||||||||||||||||
Medical condition: Hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) BG (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001997-27 | Sponsor Protocol Number: ATB_DF_001 | Start Date*: 2020-07-17 | |||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | |||||||||||||
Full Title: Rationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota | |||||||||||||
Medical condition: Diabetic foot infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003179-32 | Sponsor Protocol Number: ToL54304 | Start Date*: 2016-02-03 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment. | |||||||||||||||||||||||
Medical condition: Stroke (ischaemic stroke or intracerebral hemorrhage) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) HU (Completed) GR (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003812-22 | Sponsor Protocol Number: P903-23 | Start Date*: 2011-10-31 | |||||||||||
Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | |||||||||||||
Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA LT (Completed) LV (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002829-29 | Sponsor Protocol Number: ANRS174 | Start Date*: 2019-12-12 |
Sponsor Name:INSERM ANRS | ||
Full Title: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) | ||
Medical condition: MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002888-18 | Sponsor Protocol Number: CHAVANET-PHRC-2016 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:CHU Dijon Bourgogne | |||||||||||||
Full Title: Adjunction of daptomycin for the treatment of pneumococcal meningitis AddaMAP study | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003944-42 | Sponsor Protocol Number: REP-FAR-005 | Start Date*: 2006-12-22 | |||||||||||
Sponsor Name:REPLIDYNE, INC. | |||||||||||||
Full Title: Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo Versus Telithromycin In the Treatment of Acute Exacer... | |||||||||||||
Medical condition: Acute Exacerbation of Chronic Bronchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) LV (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002203-18 | Sponsor Protocol Number: P903-31 | Start Date*: 2012-07-18 | ||||||||||||||||||||||||||
Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With... | ||||||||||||||||||||||||||||
Medical condition: Community-acquired Bacterial Pneumonia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004486-37 | Sponsor Protocol Number: 59812 | Start Date*: 2017-09-19 | ||||||||||||||||
Sponsor Name:University Medical Centre Utrecht | ||||||||||||||||||
Full Title: FOsfomycin Randomised controlled trial for E.coli Complicated urinary tract infections as Alternative Stepdown Treatment | ||||||||||||||||||
Medical condition: Acute febrile urinary tract infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002823-27 | Sponsor Protocol Number: GAVALAGG | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:INFECTOPHARM Arzneimittel GmbH | |||||||||||||
Full Title: Placebo-kontrollierte, multizentrische, randomisierte, doppelblinde Phase III-Studie zur Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie durch add-on-Gabe v... | |||||||||||||
Medical condition: Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001838-17 | Sponsor Protocol Number: MV140-SLG-003 | Start Date*: 2015-07-17 | |||||||||||
Sponsor Name:Inmunotek, S.L.
[...]
1. Inmunotek, S.L.
2. INMUNOTEK, S.L. |
|||||||||||||
Full Title: PROSPECTIVE MULTICENTER CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND, PARALLEL-CONTROLLED VERSUS PLACEBO IN A POLYVALENT SUBLINGUAL BACTERIAL VACCINE (IN ORAL MUCOSA) TO THREE MONTHS AND SIX MONTHS IN ... | |||||||||||||
Medical condition: Recurrent Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003447-29 | Sponsor Protocol Number: DAP-PEDBAC-11-02 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO - SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. | |||||||||||||
Medical condition: Bacteremia caused by Staphylococcus Aureus. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) HU (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
